Compare ARK Genomic Revolution ETF (ARKG) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Genuine Parts Company — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Genuine Parts Company trades at $125.62 (market cap $17.29B). The key difference: Genuine Parts Company pays a 3.38% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Genuine Parts Company nearer its low. Which is the better fit depends on your goals.
| ARKG | GPC | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $149.26 |
52-Week Low | $23.09 | $92.47 |
Market Cap | — | $17.29B |
Enterprise Value | — | $23.50B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
GPC trades at $125.62, up 1.09% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $24.3B in 2025, though net margins compressed to 0.24%. Analyst consensus is mixed with 43% buy ratings and a $133 price target. Recent news highlights GPC's 70-year dividend growth streak and upcoming Q2 2026 earnings report on July 21, 2026.
GPC offers income stability with its Dividend King status but faces profitability challenges. The stock trades near analyst targets with moderate upside potential. Key risks include margin pressure from rising costs and competitive threats in auto parts distribution. Institutional sentiment remains cautiously optimistic given the stable dividend history amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
